Cargando…
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
BACKGROUND: Sodium glucose co-transporter2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical an...
Autores principales: | Nasiri-Ansari, Νarjes, Dimitriadis, Georgios K., Agrogiannis, Georgios, Perrea, Despoina, Kostakis, Ioannis D., Kaltsas, Gregory, Papavassiliou, Athanasios G., Randeva, Harpal S., Kassi, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063004/ https://www.ncbi.nlm.nih.gov/pubmed/30049285 http://dx.doi.org/10.1186/s12933-018-0749-1 |
Ejemplares similares
-
Orexin-A Exerts Equivocal Role in Atherosclerosis Process Depending on the Duration of Exposure: In Vitro Study
por: Nasiri Ansari, Narjes, et al.
Publicado: (2019) -
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE((-/-)) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
por: Nasiri-Ansari, Narjes, et al.
Publicado: (2021) -
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
por: Nasiri-Ansari, Narjes, et al.
Publicado: (2022) -
Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice
por: Zuo, Qingjuan, et al.
Publicado: (2022) -
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)